Depressed brains run hot at rest but stall under stress, ATP scans reveal

Cells in the brains and blood of young people with major depression produce more energy molecules when resting but have a reduced ability to increase energy production under stress. That paradox, identified for the first time in matching patterns across both brain and blood, points to a fundamental metabolic disturbance that could reshape how depression is diagnosed and treated.

The study, from the University of Queensland in collaboration with the University of Minnesota and published in Translational Psychiatry, analyzed levels of adenosine triphosphate (ATP), the molecule that cells use as their primary energy currency. In 18 young adults aged 18 to 25 with major depressive disorder (MDD), ATP patterns in the brain and in blood cells showed the same abnormality: overproduction at baseline, underperformance under demand.

The energy paradox in depression

If you had to guess the energy profile of a depressed person's cells, you might expect low output. Fatigue is one of the most common and difficult-to-treat symptoms of depression. But the reality is more nuanced.

Roger Varela, a researcher at the University of Queensland's Queensland Brain Institute, explains that the mitochondria, the organelles that produce ATP, appear to be working harder than normal at rest. This elevated baseline production may sound like a good thing, but it comes at a cost: the cells have a reduced capacity to ramp up energy production when demand increases, such as during cognitive effort or emotional stress.

The analogy might be an engine running at high RPM while idling. It burns fuel faster but has less headroom to accelerate when you press the gas. Over time, this pattern could wear out the cellular machinery, contributing to the progressive nature of untreated depression.

Brain and blood tell the same story

What makes this study distinctive is that it detected the ATP pattern in both tissues simultaneously. The brain imaging was performed using a technique developed by Professors Xiao Hong Zhu and Wei Chen at the University of Minnesota that directly measures ATP production rates. Blood samples were analyzed separately by the Queensland team.

The convergence matters because blood samples are easy to collect, while brain scans are expensive and limited in availability. If the blood-based ATP signature reliably tracks the brain-based one, it could serve as a practical biomarker for depression, allowing clinicians to diagnose and monitor the condition with a blood draw rather than a brain scan.

Associate Professor Susannah Tye from the Queensland Brain Institute sees this as a potential path to early intervention. Fatigue often appears before other depression symptoms solidify, and current diagnostic methods rely on subjective self-reporting. An objective cellular marker could identify depression at an earlier stage, when treatment is most effective.

Not all depression is the same

Varela emphasized that the findings reinforce a growing understanding that depression is biologically heterogeneous. Different patients show different patterns of cellular dysfunction, which may explain why the same antidepressant works well for one person and fails for another. If ATP dysregulation is a measurable dimension of a patient's depression, it could guide treatment selection toward therapies that target mitochondrial function or cellular energy metabolism.

Small study, early findings

The study included only 18 people with depression, all between 18 and 25. This is a very small sample, and the findings need replication in larger, more diverse populations. The age restriction means the results may not generalize to older adults with depression, who may have different patterns of mitochondrial dysfunction after years of illness.

The study is cross-sectional, capturing a single snapshot in time. It cannot determine whether the ATP abnormality causes depressive symptoms, results from them, or reflects an underlying vulnerability that predates the illness. Longitudinal studies tracking ATP levels over the course of depression and recovery are needed to untangle these possibilities.

The brain imaging technique, while sophisticated, is not widely available. Translating these findings into clinical practice would require validating the blood-based biomarker against clinical outcomes in much larger trials, a process that typically takes years.

Still, the finding that depression leaves a measurable metabolic signature in both brain and blood adds to the case that this is a whole-body illness with biological roots, not merely a disorder of mood or thought. For the millions of people struggling to find effective treatment, understanding the cellular mechanics could eventually mean faster, more precise help.